Carboplatin, Pegylated Liposomal Doxorubicin Hydrochloride, and Everolimus in Treating Patients With Relapsed Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and pegylated liposomal doxorubicin hydrochloride (PLD) work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving carboplatin and PLD together with everolimus may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of everolimus when given together with carboplatin and PLD in treating patients with relapsed ovarian epithelial, fallopian tube, or peritoneal cavity cancer
Fallopian Tube Cancer
Peritoneal Cavity Cancer
Recurrent Ovarian Epithelial Cancer
Drug: pegylated liposomal doxorubicin hydrochloride
Other: laboratory biomarker analysis
|Study Design:||Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||PHASE I STUDY OF CARBOPLATIN, PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) AND EVEROLIMUS IN PATIENTS WITH PLATINUM-SENSITIVE EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER IN FIRST RELAPSE|
- MTD of RAD001 in combination with carboplatin and pegulated liposomal doxorubicin [ Time Frame: About 24 weeks ] [ Designated as safety issue: Yes ]Determine the MTD of RAD001 (everolimus) in combination with carboplatin and pegylated liposomal doxorubicin. The MTD is defined as the dose level closest to, but not over that which is predicted to result in a DLT rate of 30%, the target toxicity.
- Safety/tolerability of the three drug combination of carboplatin, PLD and RAD001 based on Common Terminology Criteria for Adverse Events (CTCAE) v4.0 [ Time Frame: Every 28 days and when patient is removed from study for any reason ] [ Designated as safety issue: Yes ]Determine safety/tolerability of the three drug combination of carboplatin, PLD and RAD001. Determine preliminary analysis of anti-tumor activity of this regimen in patients with recurrent ovarian, fallopian tube or primary peritoneal cancers.
- Preliminary analysis of anti-tumor activity of this regimen in patients with recurrent ovarian, fallopian tube or primary peritoneal cancers [ Time Frame: Baseline and every 28 days ] [ Designated as safety issue: No ]
|Study Start Date:||December 2010|
|Estimated Primary Completion Date:||December 2014 (Final data collection date for primary outcome measure)|
See Detailed Description
Other Names:Drug: carboplatin
Other Names:Drug: pegylated liposomal doxorubicin hydrochloride
Other Names:Other: laboratory biomarker analysis
I. Determine the maximum tolerated dose (MTD) of RAD001 (everolimus) in combination with carboplatin and PLD.
I. Determine safety/tolerability of the three drug combination of carboplatin, PLD and RAD001 (everolimus).
II. Determine preliminary analysis of anti-tumor activity of this regimen in patients with recurrent ovarian, fallopian tube or primary peritoneal cancers.
OUTLINE: This is a dose-escalation study of everolimus.
Patients receive carboplatin intravenously (IV) and PLD IV on day 1 and everolimus orally (PO) once daily on days 1-28. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 2 months for 1 year.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01281514
|United States, Pennsylvania|
|Fox Chase Cancer Center||Recruiting|
|Philadelphia, Pennsylvania, United States, 19111-2497|
|Contact: Lainie P. Martin 215-728-2814 firstname.lastname@example.org|
|Principal Investigator: Lainie P. Martin|
|Principal Investigator:||Lainie Martin||Fox Chase Cancer Center|